2seventy bio, Inc. (TSVT)
- Previous Close
5.0000 - Open
4.9900 - Bid 4.7900 x 100
- Ask 4.8200 x 100
- Day's Range
4.7000 - 5.0300 - 52 Week Range
1.5350 - 12.6900 - Volume
239,767 - Avg. Volume
1,055,198 - Market Cap (intraday)
246.746M - Beta (5Y Monthly) 1.87
- PE Ratio (TTM)
-- - EPS (TTM)
-4.3500 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.50
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
www.2seventybio.comRecent News: TSVT
Performance Overview: TSVT
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSVT
Valuation Measures
Market Cap
246.75M
Enterprise Value
318.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.47
Price/Book (mrq)
1.19
Enterprise Value/Revenue
4.47
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.31%
Return on Equity (ttm)
-73.34%
Revenue (ttm)
71.2M
Net Income Avi to Common (ttm)
-223.22M
Diluted EPS (ttm)
-4.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
181.38M
Total Debt/Equity (mrq)
122.00%
Levered Free Cash Flow (ttm)
-104.28M
Research Analysis: TSVT
Company Insights: TSVT
TSVT does not have Company Insights